The estimated Net Worth of Zeev Bronfeld is at least $21.3 Milión dollars as of 13 August 2014. Mr. Bronfeld owns over 4,400,000 units of Protalix BioTherapeutics stock worth over $10,468,972 and over the last 10 years he sold PLX stock worth over $10,868,000. In addition, he makes $0 as Chairman of the Board at Protalix BioTherapeutics.
Zeev has made over 1 trades of the Protalix BioTherapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 4,400,000 units of PLX stock worth $10,868,000 on 13 August 2014.
The largest trade he's ever made was selling 4,400,000 units of Protalix BioTherapeutics stock on 13 August 2014 worth over $10,868,000. On average, Zeev trades about 880,000 units every 0 days since 2014. As of 13 August 2014 he still owns at least 10,066,319 units of Protalix BioTherapeutics stock.
You can see the complete history of Mr. Bronfeld stock trades at the bottom of the page.
Zeev (Tom) Bronfeld has been appointed Chairman of the Board at Protalix Biotherapeutics, Inc. effective August 13, 2019. His work experience includes the following roles: Director at the Company (December 31, 2006-March 9, 2010), Independent Interim Chairman of the Board at the Company (March 9, 2010-July 24, 2014), Independent Director at the Company (July 24, 2014-August 13, 2019), Chairman of the Board at D.N.A Biomedical Solutions Ltd., Director at Entera Bio Ltd (a Subsidiary of D.N.A Biomedical Solutions Ltd.), Chief Executive Officer and Director at Bio-Cell Ltd and Director at LN Technological Initiatives Ltd, D. Medical Industries Ltd, Biomedix Incubator Ltd, MEITAV Technological Initiative Center Ltd, Contif Ltd, Nilimedix Ltd, Cindolor Medical Ltd, G-Sense Ltd, TIF Ventures Ltd, Macro Cure Ltd, Medex-Set Ltd, Braintact Ltd, Engio B Ltd, EBC Investments Ltd, Plosense Ltd and Spearhead Bio Investments Ltd. Mr. Bronfeld holds a Bachelors degree in Economics from The Hebrew University of Jerusalem.
Zeev Bronfeld is 69, he's been the Chairman of the Board of Protalix BioTherapeutics since 2019. There are 2 older and 11 younger executives at Protalix BioTherapeutics. The oldest executive at Protalix BioTherapeutics Inc. is Aharon Schwartz, 75, who is the Independent Director.
Zeev's mailing address filed with the SEC is C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET SCIENCE PARK, POB 455, CARMIEL, L3, 2161401.
Over the last 18 years, insiders at Protalix BioTherapeutics have traded over $46,705,936 worth of Protalix BioTherapeutics stock and bought 4,403,619 units worth $4,673,005 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Capital Management Lp Camber a Ltd Bio Cell. On average, Protalix BioTherapeutics executives and independent directors trade stock every 88 days with the average trade being worth of $404,231. The most recent stock trade was executed by Dror Bashan on 19 October 2023, trading 64,516 units of PLX stock currently worth $90,322.
protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher´s disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa‐galactosidase
Protalix BioTherapeutics executives and other stock owners filed with the SEC include: